# US 2017/0281724 A9 · Use of gelsolin to diagnose and treat inflammatory diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0281724 A9
- Document ID: US20170281724A9
- Status: Published application
- Kind: A9
- Application number: 15/131,465
- Filed: 2016-04-18
- Published: 2017-10-05
- Earliest claimed: 2006-03-15
- Assignees: The Brigham and Women's Hospital, Inc.
- Applicants: The Brigham and Women's Hospital, Inc.
- Inventors: Thomas P. Stossel; Teresia Anna Charlotta Magnuson Osborn; Andrej Tarkowski
- Web page: https://patentgrep.com/patent/US20170281724A9

## CPC

- A61K 38/1709: {from mammals}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 5/14: of the thyroid hormones, e.g. T3, T4
- A61P 5/38: of the suprarenal hormones
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 11/06: Antiasthmatics
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/02: Immunomodulators
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- G01N 33/564: for pre-existing immune complex or autoimmune disease {, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9}
- G01N 33/6887: {from muscle, cartilage or connective tissue}
- G01N 2333/4703: Regulators; Modulating activity
- G01N 2333/4712: Muscle proteins, e.g. myosin, actin, protein
- G01N 2800/102: Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
- G01N 2800/104: Lupus erythematosus [SLE]
- G01N 2800/24: Immunology or allergic disorders
- G01N 2800/50: Determining the risk of developing a disease
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The invention relates to the use of gelsolin to treat inflammatory diseases (e.g., rheumatoid arthritis) and to the use of gelsolin to diagnose, monitor, and evaluate therapies of inflammatory diseases (e.g., rheumatoid arthritis).

## Claims

### Claim 1

A method for characterizing a subject's risk profile of developing a future inflammatory disease, comprising:
obtaining a level of gelsolin in the subject,
comparing the level of the gelsolin to a predetermined value, and
characterizing the subject's risk profile of developing an inflammatory disease based upon the level of gelsolin in comparison to the predetermined value, wherein a level of gelsolin at or below the predetermined level is indicative that the subject is at an elevated risk of developing the inflammatory disease, and wherein a level of gelsolin at or above the predetermined level is indicative that the subject is not at an elevated risk of developing the inflammatory disease.

### Claim 2 (depends on 1)

The method of claim 1, wherein the inflammatory disease is arthritis, rheumatoid arthritis, asthma, inflammatory bowel disease (Crohn's disease or ulcerative colitis), chronic obstructive pulmonary disease (COPD), allergic rhinitis, vasculitis (polyarteritis nodosa, temporal arteritis, Wegener's granulomatosus, Takayasu's arteritis, or Behcet syndrome), inflammatory neuropathy, psoriasis, systemic lupus erythematosis (SLE), chronic thyroiditis, Hashimoto's thyroiditis, Addison's disease, polymyalgia rheumatica, Sjogren's syndrome, or Churg-Strauss syndrome.

### Claim 3 (depends on 2)

The method of claim 2, wherein the inflammatory disease is rheumatoid arthritis.

### Claim 4 (depends on 1)

The method of claim 1, wherein the level of gelsolin is in a body fluid of the subject.

### Claim 5 (depends on 4)

The method of claim 4, wherein the body fluid is blood, plasma, serum, urine, synovial fluid, or alveolar fluid.

### Claim 6 (depends on 1)

The method of claim 1, wherein the level of gelsolin is in a body tissue of the subject.

### Claim 7 (depends on 6)

The method of claim 6, wherein the body tissue is a joint, gastrointestinal, thyroid, adrenal, vascular, pulmonary, renal, cardiac, skin, ocular, brain, pancreatic, liver, nerve, or muscle tissue.

### Claim 8 (depends on 1)

The method of claim 1, wherein the predetermined value is about 250 mg/L of plasma or lower.

### Claim 9 (depends on 1)

The method of claim 1, wherein the subject is an apparently healthy subject.

### Claim 10 (depends on 1)

The method of claim 1 further comprising performing one or more tests to evaluate the inflammatory disease.

### Claim 11 (depends on 10)

The method of claim 10, wherein the test is measuring a level of a marker of inflammation in the subject.

### Claim 12 (depends on 11)

The method of claim 11, wherein the marker of inflammation is CRP, soluble intercellular adhesion molecule (sICAM-1), ICAM 3, BL-CAM, LFA-2, VCAM-1, NCAM, PECAM, fibrinogen, serum amyloid A (SAA), lipoprotein associated phospholipase A2 (LpPlA2), sCD40 ligand (sCD40L), myeloperoxidase, Interleukin-6 (IL-6), or Interleukin-8 (IL-8).

### Claim 13

A method for characterizing a subject's risk profile of developing a future inflammatory disease, comprising:
obtaining a level of gelsolin in the subject,
comparing the level of the gelsolin to a first predetermined value to establish a first risk value,
obtaining a level of a second marker of inflammation in the subject,
comparing the level of the second marker of inflammation to a second predetermined value to establish a second risk value, and
characterizing the subject's risk profile of developing the inflammatory disease based upon the combination of the first risk value and the second risk value, wherein the combination of the first risk value and second risk value establishes a third risk value different from said first and second risk values.

### Claim 14 (depends on 13)

The method of claim 13, wherein said subject is an apparently healthy subject.

### Claim 15 (depends on 13)

The method of claim 13, wherein the first predetermined value is about 250 mg/L of plasma or lower.

### Claim 16 (depends on 13)

The method of claim 13, wherein the first predetermined value is a plurality of predetermined gelsolin level ranges, one of said plurality being below about 250 mg/L of plasma and another of said ranges being above about 250 mg/L of plasma, and wherein said comparing step comprises determining in which of said plurality of predetermined gelsolin level ranges said subject's gelsolin level falls.

### Claim 17 (depends on 13)

The method of claim 13, wherein the inflammatory disease is arthritis, rheumatoid arthritis, asthma, inflammatory bowel disease (Crohn's disease or ulcerative colitis), chronic obstructive pulmonary disease (COPD), allergic rhinitis, vasculitis (polyarteritis nodosa, temporal arteritis, Wegener's granulomatosus, Takayasu's arteritis, or Behcet syndrome), inflammatory neuropathy, psoriasis, systemic lupus erythematosis (SLE), chronic thyroiditis, Hashimoto's thyroiditis, Addison's disease, polymyalgia rheumatica, Sjogren's syndrome, or Churg-Strauss syndrome.

### Claim 18 (depends on 17)

The method of claim 17, wherein the inflammatory disease is rheumatoid arthritis.

### Claim 19

A method for treating a subject having or at risk of developing an inflammatory disease comprising:
administering an effective amount of gelsolin to a subject in need of such a treatment to treat the subject.

### Claim 20

A method for treating a subject having or at risk of developing an inflammatory disease comprising:
administering an effective amount of gelsolin to a subject in need of such a treatment to raise the level of gelsolin in the subject above a predetermined value.

### Claim 21 (depends on 19, 20)

The method of claim 19 or 20, wherein the subject is otherwise free of indications calling for treatment with gelsolin.

### Claim 22 (depends on 19, 20)

The method of claim 19 or 20, wherein the inflammatory disease is arthritis, rheumatoid arthritis, asthma, inflammatory bowel disease (Crohn's disease or ulcerative colitis), chronic obstructive pulmonary disease (COPD), allergic rhinitis, vasculitis (polyarteritis nodosa, temporal arteritis, Wegener's granulomatosus, Takayasu's arteritis, or Behcet syndrome), inflammatory neuropathy, psoriasis, systemic lupus erythematosis (SLE), chronic thyroiditis, Hashimoto's thyroiditis, Addison's disease, polymyalgia rheumatica, Sjogren's syndrome, or Churg-Strauss syndrome.

### Claim 23 (depends on 22)

The method of claim 22, wherein the inflammatory disease is rheumatoid arthritis.

### Claim 24 (depends on 19, 20)

The method of claim 19 or 20, wherein the gelsolin is plasma gelsolin (pGSN), cytoplasmic gelsolin (cGSN), advillin, villin, capG, flightless proteins, fragmin, severin, adseverin, protovillin, or supervillin.

### Claim 25 (depends on 19, 20)

The method of claim 19 or 20, wherein the gelsolin is administered orally, sublingually, buccally, intranasally, intravenously, intramuscularly, intraarticularly, intraperitoneally, subcutaneously, or topically.

### Claim 26 (depends on 19, 20)

The method of claim 19 or 20, wherein the gelsolin is administered prophylactically.

### Claim 27 (depends on 19, 20, 23)

The method of claim 19, 20 or 23 further comprising administering a second agent for treating the inflammatory disease.

### Claim 28 (depends on 27)

The method of claim 27, wherein the second agent for treating the inflammatory disease is Alclofenac, Alclometasone Dipropionate, Algestone Acetonide, Alpha Amylase, Amcinafal, Amcinafide, Amfenac Sodium, Amiprilose Hydrochloride, Anakinra, Anirolac, Anitrazafen, Apazone, Balsalazide Disodium, Bendazac, Benoxaprofen, Benzydamine Hydrochloride, Bromelains, Broperamole, Budesonide, Carprofen, Cicloprofen, Cintazone, Cliprofen, Clobetasol Propionate, Clobetasone Butyrate, Clopirac, Cloticasone Propionate, Cormethasone Acetate, Cortodoxone, Cyclooxygenase-2 (COX-2) inhibitor, Deflazacort, Desonide, Desoximetasone, Dexamethasone Dipropionate, Diclofenac Potassium, Diclofenac Sodium, Diflorasone Diacetate, Diflumidone Sodium, Diflunisal, Difluprednate, Diftalone, Dimethyl Sulfoxide, Drocinonide, Endrysone, Enlimomab, Enolicam Sodium, Epirizole, Etodolac, Etofenamate, Felbinac, Fenamole, Fenbufen, Fenclofenac, Fenclorac, Fendosal, Fenpipalone, Fentiazac, Flazalone, Fluazacort, Flufenamic Acid, Flumizole, Flunisolide Acetate, Flunixin, Flunixin Meglumine, Fluocortin Butyl, Fluorometholone Acetate, Fluquazone, Flurbiprofen, Fluretofen, Fluticasone Propionate, Furaprofen, Furobufen, Halcinonide, Halobetasol Propionate, Halopredone Acetate, Ibufenac, Ibuprofen, Ibuprofen Aluminum, Ibuprofen Piconol, Ilonidap, Indomethacin, Indomethacin Sodium, Indoprofen, Indoxole, Intrazole, Isoflupredone Acetate, Isoxepac, Isoxicam, Ketoprofen, Lofemizole Hydrochloride, Lornoxicam, Loteprednol Etabonate, Meclofenamate Sodium, Meclofenamic Acid, Meclorisone Dibutyrate, Mefenamic Acid, Mesalamine, Meseclazone, Methylprednisolone Suleptanate, Morniflumate, Nabumetone, Naproxen, Naproxen Sodium, Naproxol, Nimazone, Olsalazine Sodium, Orgotein, Orpanoxin, Oxaprozin, Oxyphenbutazone, Paranyline Hydrochloride, Pentosan Polysulfate Sodium, Phenbutazone Sodium Glycerate, Pirfenidone, Piroxicam, Piroxicam Cinnamate, Piroxicam Olamine, Pirprofen, Prednazate, Prifelone, Prodolic Acid, Proquazone, Proxazole, Proxazole Citrate, Rimexolone, Romazarit, Salcolex, Salnacedin, Salsalate, Sanguinarium Chloride, Seclazone, Sermetacin, Sudoxicam, Sulindac, Suprofen, Talmetacin, Talniflumate, Talosalate, Tebufelone, Tenidap, Tenidap Sodium, Tenoxicam, Tesicam, Tesimide, Tetrydamine, Tiopinac, Tixocortol Pivalate, Tolmetin, Tolmetin Sodium, Triclonide, Triflumidate, Zidometacin, or Zomepirac Sodium.

### Claim 29 (depends on 23)

The method of claim 23 further comprising administering a second agent for treating rheumatoid arthritis.

### Claim 30 (depends on 29)

The method of claim 29, wherein the second agent for treating rheumatoid arthritis is hydroxychloroquine (Plaquenil), chloroquine (Aralen), methotrexate, sulfasalazine (Azulfidine), Leflunomide (Arava), azathioprine (Imuran), penicillamine (Cuprimine or Depen), Gold salts (Ridaura or Aurolate), minocycline (Dynacin or Minocin), cyclosporine (Neoral or Sandimmune) cyclophosphamide (Cytoxan or Neosar), Etanercept (Enbrel), Infliximab (Remicade), Anakinra (Kineret) or Adalimumab (Humira).

### Claim 31

A method for treating a subject to reduce the risk of an inflammatory disease comprising
selecting a subject on the basis that the subject is known to have a below-normal level of gelsolin and
administering gelsolin to the subject and/or a second agent in an effective amount to reduce the risk of the subject developing the inflammatory disease.

### Claim 32

A method for treating a subject to reduce the risk of an inflammatory disease comprising
selecting a subject on the basis that the subject is known to have a below-normal level of gelsolin and
administering gelsolin to the subject and/or a second agent in an effective amount to raise the level of gelsolin in the subject above a predetermined value.

### Claim 33 (depends on 31, 32)

The method of claim 31 or 32, wherein the subject is otherwise free of indications calling for treatment with gelsolin.

### Claim 34 (depends on 31, 32)

The method of claim 31 or 32, wherein the inflammatory disease is arthritis, rheumatoid arthritis, asthma, inflammatory bowel disease (Crohn's disease or ulcerative colitis), chronic obstructive pulmonary disease (COPD), allergic rhinitis, vasculitis (polyarteritis nodosa, temporal arteritis, Wegener's granulomatosus, Takayasu's arteritis, or Behcet syndrome), inflammatory neuropathy, psoriasis, systemic lupus erythematosis (SLE), chronic thyroiditis, Hashimoto's thyroiditis, Addison's disease, polymyalgia rheumatica, Sjogren's syndrome, or Churg-Strauss syndrome.

### Claim 35 (depends on 34)

The method of claim 34, wherein the inflammatory disease is rheumatoid arthritis.

### Claim 36 (depends on 31, 32)

The method of claim 31 or 32, wherein the gelsolin is plasma gelsolin (pGSN), cytoplasmic gelsolin (cGSN), advillin, villin, capG, flightless proteins, fragmin, severin, adseverin, protovillin, or supervillin.

### Claim 37 (depends on 31, 32)

The method of claim 31 or 32, wherein the subject is apparently healthy.

### Claim 38 (depends on 31, 32, 35)

The method of claim 31, 32 or 35 further comprising administering a second agent for treating the inflammatory disease.

### Claim 39 (depends on 38)

The method of claim 38, wherein the second agent for treating the inflammatory disease is Alclofenac, Alclometasone Dipropionate, Algestone Acetonide, Alpha Amylase, Amcinafal, Amcinafide, Amfenac Sodium, Amiprilose Hydrochloride, Anakinra, Anirolac, Anitrazafen, Apazone, Balsalazide Disodium, Bendazac, Benoxaprofen, Benzydamine Hydrochloride, Bromelains, Broperamole, Budesonide, Carprofen, Cicloprofen, Cintazone, Cliprofen, Clobetasol Propionate, Clobetasone Butyrate, Clopirac, Cloticasone Propionate, Cormethasone Acetate, Cortodoxone, Cyclooxygenase-2 (COX-2) inhibitor, Deflazacort, Desonide, Desoximetasone, Dexamethasone Dipropionate, Diclofenac Potassium, Diclofenac Sodium, Diflorasone Diacetate, Diflumidone Sodium, Diflunisal, Difluprednate, Diftalone, Dimethyl Sulfoxide, Drocinonide, Endrysone, Enlimomab, Enolicam Sodium, Epirizole, Etodolac, Etofenamate, Felbinac, Fenamole, Fenbufen, Fenclofenac, Fenclorac, Fendosal, Fenpipalone, Fentiazac, Flazalone, Fluazacort, Flufenamic Acid, Flumizole, Flunisolide Acetate, Flunixin, Flunixin Meglumine, Fluocortin Butyl, Fluorometholone Acetate, Fluquazone, Flurbiprofen, Fluretofen, Fluticasone Propionate, Furaprofen, Furobufen, Halcinonide, Halobetasol Propionate, Halopredone Acetate, Ibufenac, Ibuprofen, Ibuprofen Aluminum, Ibuprofen Piconol, Ilonidap, Indomethacin, Indomethacin Sodium, Indoprofen, Indoxole, Intrazole, Isoflupredone Acetate, Isoxepac, Isoxicam, Ketoprofen, Lofemizole Hydrochloride, Lornoxicam, Loteprednol Etabonate, Meclofenamate Sodium, Meclofenamic Acid, Meclorisone Dibutyrate, Mefenamic Acid, Mesalamine, Meseclazone, Methylprednisolone Suleptanate, Morniflumate, Nabumetone, Naproxen, Naproxen Sodium, Naproxol, Nimazone, Olsalazine Sodium, Orgotein, Orpanoxin, Oxaprozin, Oxyphenbutazone, Paranyline Hydrochloride, Pentosan Polysulfate Sodium, Phenbutazone Sodium Glycerate, Pirfenidone, Piroxicam, Piroxicam Cinnamate, Piroxicam Olamine, Pirprofen, Prednazate, Prifelone, Prodolic Acid, Proquazone, Proxazole, Proxazole Citrate, Rimexolone, Romazarit, Salcolex, Salnacedin, Salsalate, Sanguinarium Chloride, Seclazone, Sermetacin, Sudoxicam, Sulindac, Suprofen, Talmetacin, Talniflumate, Talosalate, Tebufelone, Tenidap, Tenidap Sodium, Tenoxicam, Tesicam, Tesimide, Tetrydamine, Tiopinac, Tixocortol Pivalate, Tolmetin, Tolmetin Sodium, Triclonide, Triflumidate, Zidometacin, or Zomepirac Sodium.

### Claim 40 (depends on 35)

The method of claim 35 further comprising administering a second agent for treating rheumatoid arthritis.

### Claim 41 (depends on 40)

The method of claim 40, wherein the second agent for treating rheumatoid arthritis is hydroxychloroquine (Plaquenil), chloroquine (Aralen), methotrexate, sulfasalazine (Azulfidine), Leflunomide (Arava), azathioprine (Imuran), penicillamine (Cuprimine or Depen), Gold salts (Ridaura or Aurolate), minocycline (Dynacin or Minocin), cyclosporine (Neoral or Sandimmune) cyclophosphamide (Cytoxan or Neosar), Etanercept (Enbrel), Infliximab (Remicade), Anakinra (Kineret) or Adalimumab (Humira).

### Claim 42

A method for treating a subject with a below-normal level of gelsolin comprising:
(i) treating the subject with a first therapy for treating or reducing the risk of an inflammatory disease,
(ii) obtaining a level of gelsolin in the subject,
(iii) comparing the level of gelsolin obtained in (ii) to a predetermined value corresponding to a predetermined level of gelsolin, and if the predetermined level of gelsolin is not reached,
(iv) treating the subject with a second agent for treating or reducing the risk of the inflammatory disease, and repeating (ii) and (iii) until the predetermined level of gelsolin is reached.

### Claim 43 (depends on 42)

The method of claim 42, wherein the predetermined level of gelsolin is a level of gelsolin in an apparently healthy control population.

### Claim 44 (depends on 42)

The method of claim 42, wherein the predetermined value is about 250 mg/L of plasma or higher.

### Claim 45 (depends on 42)

The method of claim 42, wherein the inflammatory disease is arthritis, rheumatoid arthritis, asthma, inflammatory bowel disease (Crohn's disease or ulcerative colitis), chronic obstructive pulmonary disease (COPD), allergic rhinitis, vasculitis (polyarteritis nodosa, temporal arteritis, Wegener's granulomatosus, Takayasu's arteritis, or Behcet syndrome), inflammatory neuropathy, psoriasis, systemic lupus erythematosis (SLE), chronic thyroiditis, Hashimoto's thyroiditis, Addison's disease, polymyalgia rheumatica, Sjogren's syndrome, or Churg-Strauss syndrome.

### Claim 46 (depends on 45)

The method of claim 45, wherein the inflammatory disease is rheumatoid arthritis.

### Claim 47 (depends on 42)

The method of claim 42, wherein the second agent for treating or reducing the risk of the inflammatory disease is Alclofenac, Alclometasone Dipropionate, Algestone Acetonide, Alpha Amylase, Amcinafal, Amcinafide, Amfenac Sodium, Amiprilose Hydrochloride, Anakinra, Anirolac, Anitrazafen, Apazone, Balsalazide Disodium, Bendazac, Benoxaprofen, Benzydamine Hydrochloride, Bromelains, Broperamole, Budesonide, Carprofen, Cicloprofen, Cintazone, Cliprofen, Clobetasol Propionate, Clobetasone Butyrate, Clopirac, Cloticasone Propionate, Cormethasone Acetate, Cortodoxone, Cyclooxygenase-2 (COX-2) inhibitor, Deflazacort, Desonide, Desoximetasone, Dexamethasone Dipropionate, Diclofenac Potassium, Diclofenac Sodium, Diflorasone Diacetate, Diflumidone Sodium, Diflunisal, Difluprednate, Diftalone, Dimethyl Sulfoxide, Drocinonide, Endrysone, Enlimomab, Enolicam Sodium, Epirizole, Etodolac, Etofenamate, Felbinac, Fenamole, Fenbufen, Fenclofenac, Fenclorac, Fendosal, Fenpipalone, Fentiazac, Flazalone, Fluazacort, Flufenamic Acid, Flumizole, Flunisolide Acetate, Flunixin, Flunixin Meglumine, Fluocortin Butyl, Fluorometholone Acetate, Fluquazone, Flurbiprofen, Fluretofen, Fluticasone Propionate, Furaprofen, Furobufen, Halcinonide, Halobetasol Propionate, Halopredone Acetate, Ibufenac, Ibuprofen, Ibuprofen Aluminum, Ibuprofen Piconol, Ilonidap, Indomethacin, Indomethacin Sodium, Indoprofen, Indoxole, Intrazole, Isoflupredone Acetate, Isoxepac, Isoxicam, Ketoprofen, Lofemizole Hydrochloride, Lornoxicam, Loteprednol Etabonate, Meclofenamate Sodium, Meclofenamic Acid, Meclorisone Dibutyrate, Mefenamic Acid, Mesalamine, Meseclazone, Methylprednisolone Suleptanate, Morniflumate, Nabumetone, Naproxen, Naproxen Sodium, Naproxol, Nimazone, Olsalazine Sodium, Orgotein, Orpanoxin, Oxaprozin, Oxyphenbutazone, Paranyline Hydrochloride, Pentosan Polysulfate Sodium, Phenbutazone Sodium Glycerate, Pirfenidone, Piroxicam, Piroxicam Cinnamate, Piroxicam Olamine, Pirprofen, Prednazate, Prifelone, Prodolic Acid, Proquazone, Proxazole, Proxazole Citrate, Rimexolone, Romazarit, Salcolex, Salnacedin, Salsalate, Sanguinarium Chloride, Seclazone, Sermetacin, Sudoxicam, Sulindac, Suprofen, Talmetacin, Talniflumate, Talosalate, Tebufelone, Tenidap, Tenidap Sodium, Tenoxicam, Tesicam, Tesimide, Tetrydamine, Tiopinac, Tixocortol Pivalate, Tolmetin, Tolmetin Sodium, Triclonide, Triflumidate, Zidometacin, or Zomepirac Sodium.

### Claim 48 (depends on 46)

The method of claim 46 further comprising administering a second agent for treating rheumatoid arthritis.

### Claim 49 (depends on 48)

The method of claim 48, wherein the second agent for treating rheumatoid arthritis is hydroxychloroquine (Plaquenil), chloroquine (Aralen), methotrexate, sulfasalazine (Azulfidine), Leflunomide (Arava), azathioprine (Imuran), penicillamine (Cuprimine or Depen), Gold salts (Ridaura or Aurolate), minocycline (Dynacin or Minocin), cyclosporine (Neoral or Sandimmune) cyclophosphamide (Cytoxan or Neosar), Etanercept (Enbrel), Infliximab (Remicade), Anakinra (Kineret) or Adalimumab (Humira).

### Claim 50

A method for evaluating the efficacy of a therapy for treating or reducing the risk of an inflammatory disease in a subject comprising:
(i) obtaining a level of gelsolin in a subject undergoing therapy with an agent to treat or reduce the risk of an inflammatory disease,
(ii) comparing the level of gelsolin obtained in (i) to a predetermined value corresponding to a level of gelsolin in an apparently healthy control population, and
(iii) determining whether the level of gelsolin in (i) is at or above the predetermined level, said determination being indicative of whether the therapy is efficacious.

### Claim 51 (depends on 50)

The method of claim 50, wherein step (i) and step (ii) and/or step (iii) are repeated so as to monitor the subject's levels of gelsolin over time.

### Claim 52 (depends on 50)

The method of claim 50, wherein the predetermined value is about 250 mg/L of plasma or lower.

### Claim 53 (depends on 50)

The method of claim 50, wherein the agent is gelsolin, Alclofenac, Alclometasone Dipropionate, Algestone Acetonide, Alpha Amylase, Amcinafal, Amcinafide, Amfenac Sodium, Amiprilose Hydrochloride, Anakinra, Anirolac, Anitrazafen, Apazone, Balsalazide Disodium, Bendazac, Benoxaprofen, Benzydamine Hydrochloride, Bromelains, Broperamole, Budesonide, Carprofen, Cicloprofen, Cintazone, Cliprofen, Clobetasol Propionate, Clobetasone Butyrate, Clopirac, Cloticasone Propionate, Cormethasone Acetate, Cortodoxone, Cyclooxygenase-2 (COX-2) inhibitor, Deflazacort, Desonide, Desoximetasone, Dexamethasone Dipropionate, Diclofenac Potassium, Diclofenac Sodium, Diflorasone Diacetate, Diflumidone Sodium, Diflunisal, Difluprednate, Diftalone, Dimethyl Sulfoxide, Drocinonide, Endrysone, Enlimomab, Enolicam Sodium, Epirizole, Etodolac, Etofenamate, Felbinac, Fenamole, Fenbufen, Fenclofenac, Fenclorac, Fendosal, Fenpipalone, Fentiazac, Flazalone, Fluazacort, Flufenamic Acid, Flumizole, Flunisolide Acetate, Flunixin, Flunixin Meglumine, Fluocortin Butyl, Fluorometholone Acetate, Fluquazone, Flurbiprofen, Fluretofen, Fluticasone Propionate, Furaprofen, Furobufen, Halcinonide, Halobetasol Propionate, Halopredone Acetate, Ibufenac, Ibuprofen, Ibuprofen Aluminum, Ibuprofen Piconol, Ilonidap, Indomethacin, Indomethacin Sodium, Indoprofen, Indoxole, Intrazole, Isoflupredone Acetate, Isoxepac, Isoxicam, Ketoprofen, Lofemizole Hydrochloride, Lornoxicam, Loteprednol Etabonate, Meclofenamate Sodium, Meclofenamic Acid, Meclorisone Dibutyrate, Mefenamic Acid, Mesalamine, Meseclazone, Methylprednisolone Suleptanate, Morniflumate, Nabumetone, Naproxen, Naproxen Sodium, Naproxol, Nimazone, Olsalazine Sodium, Orgotein, Orpanoxin, Oxaprozin, Oxyphenbutazone, Paranyline Hydrochloride, Pentosan Polysulfate Sodium, Phenbutazone Sodium Glycerate, Pirfenidone, Piroxicam, Piroxicam Cinnamate, Piroxicam Olamine, Pirprofen, Prednazate, Prifelone, Prodolic Acid, Proquazone, Proxazole, Proxazole Citrate, Rimexolone, Romazarit, Salcolex, Salnacedin, Salsalate, Sanguinarium Chloride, Seclazone, Sermetacin, Sudoxicam, Sulindac, Suprofen, Talmetacin, Talniflumate, Talosalate, Tebufelone, Tenidap, Tenidap Sodium, Tenoxicam, Tesicam, Tesimide, Tetrydamine, Tiopinac, Tixocortol Pivalate, Tolmetin, Tolmetin Sodium, Triclonide, Triflumidate, Zidometacin, Zomepirac Sodium, hydroxychloroquine (Plaquenil), chloroquine (Aralen), methotrexate, sulfasalazine (Azulfidine), Leflunomide (Arava), azathioprine (Imuran), penicillamine (Cuprimine or Depen), Gold salts (Ridaura or Aurolate), minocycline (Dynacin or Minocin), cyclosporine (Neoral or Sandimmune) cyclophosphamide (Cytoxan or Neosar), Etanercept (Enbrel), Infliximab (Remicade), Anakinra (Kineret) or Adalimumab (Humira)

### Claim 54

A method for deciding on the course of a therapy in a subject, comprising:
(i) obtaining a level of gelsolin in a subject undergoing a therapy to treat or reduce the risk of an inflammatory disease,
(ii) comparing the level of gelsolin obtained in (i) to a predetermined value corresponding to a level of gelsolin,
(iii) determining whether the level of gelsolin obtained in (i) is at or below the predetermined level, and
(iv) deciding on the course of the therapy based on such determination.

### Claim 55 (depends on 54)

The method of claim 54, wherein the predetermined level of gelsolin is a level of gelsolin in an apparently healthy control population.

### Claim 56 (depends on 54)

The method of claim 54, wherein step (i) and step (ii) and for step (iii) are repeated so as to monitor the subject's level of gelsolin over time.

### Claim 57 (depends on 54)

The method of claim 54, wherein the predetermined value is about 250 mg/L of plasma or lower.
